• KOL
    • KOLs Community
    • Waldenström
    • Waldenström Macroglobulinemia
    • Jorge J Castillo
    • Jorge J Castillo

      Jorge J Castillo

      Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. | Bing Center for Waldenström Macroglobulinemia, Dana-Farber ...



      KOL Resume for Jorge J Castillo


      Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

      Hematology, Dana Farber Cancer Institute, Boston, United States of America

      Hematologic Oncology Treatment Center, Dana‐Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

      Dana-Farber Cancer Institute, Boston, Massachusetts, United States


      Harvard Medical School, Bing Center for Waldenstrom's Macroglobulinemia, Boston, USA

      Bing Center for Waldenstrom's Macroglobulinemia.

      Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA


      Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

      7Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center.

      Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.

      Division of Hematologic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts

      Department of Medicine, Harvard Medical School, Boston, MA


      Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

      3 Harvard Medical School, Boston, MA.

      Dana-Farber Cancer Institute, Boston, MA


      Bing Center for Waldenström's Macroglobulinemia Dana‐Farber Cancer Institute Boston Massachusetts

      Department of Medical Oncology, Dana Farber Cancer Institute, and.

      Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;,

      Harvard Medical School, Boston, MA; and

      Dana Farber Cancer Institute;



      Jorge J Castillo: Influence Statistics

      Sample of concepts for which Jorge J Castillo is among the top experts in the world.
      Concept World rank
      plasma endogenous synthesis #1
      61 special issues #1
      américa latina demostrado #1
      plasmablastic lymphoma doxorubicin #1
      hhv8 dlbcl #1
      outcome pbl #1
      bilateral extranodal mzl #1
      diffuse mouth neoplasms #1
      21 patients bortezomib #1
      involvement subcutaneous tissue #1
      claimsbased eventfree survival #1
      pbl aggressive #1
      pathological diagnosis novo #1
      novo nodal #1
      differential responses agents #1
      patients hivassociated pbl #1
      harbinger multiple myeloma #1
      mcl mzl lpl #1
      bmi dlbcl incidence #1
      alk lbcl pel #1
      pandemia sars #1
      nlr ptclu #1
      driven malignant transformation #1
      bmi aml #1
      prognostic ebv #1
      pel plasmablastic lymphoma #1
      double expressors #1
      potential relationship htlv1 #1
      biological mechanisms lymphomagenesis #1
      pandemia sars cov2 #1
      chemotherapy pel #1
      careful workup steps #1
      rituximab chemo #1
      cutaneous involvement survival #1
      hr162 95 #1
      infusional dose‐adjusted epoch #1
      resistant cll patients #1
      awareness rare malignancies #1
      patients nmzl #1
      location 58yearold #1
      classically immunophenotype #1
      41–87 #1
      pi3k inhibitors advances #1
      rare cd20negative variants #1
      lactic antigens #1
      4 prospective cohort #1
      current female smokers #1
      large b‐cell lymphoma #1
      goal overdiagnosis #1
      treatment bns #1


      Prominent publications by Jorge J Castillo

      KOL-Index: 18563

      Activating mutations in MYD88 are present in ∼95% of patients with Waldenström macroglobulinemia (WM), as well as other B-cell malignancies including activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL). In WM, mutated MYD88 triggers activation of Bruton tyrosine kinase (BTK). Ibrutinib, a pleiotropic kinase inhibitor that targets BTK, is highly active in patients with mutated MYD88. We observed that mutated MYD88 WM and ABC DLBCL cell lines, as well as primary WM cells show ...

      Known for Mutated Myd88 | Btk Ibrutinib | Activation Hck | Large Bcell | Cell Kinase
      KOL-Index: 12895

      Approximately a third of the patients with diffuse large B-cell lymphoma present with extranodal involvement. Our study aims to identify primary extranodal sites of disease associated with prognosis in patients with diffuse large B-cell lymphoma (DLBCL) in the rituximab era. A secondary objective is to describe epidemiological and clinical characteristics of patients with extranodal DLBCL. We included adult patients from the Surveillance, Epidemiology and End Results (SEER) database ...

      Known for Extranodal Involvement | Diffuse Large | Cell Lymphoma | Patients Dlbcl | Antibodies Monoclonal
      KOL-Index: 12836

      BACKGROUND: In the era of widespread rituximab use for Waldenström's macroglobulinaemia, new treatment options for patients with rituximab-refractory disease are an important clinical need. Ibrutinib has induced durable responses in previously treated patients with Waldenström's macroglobulinaemia. We assessed the efficacy and safety of ibrutinib in a population with rituximab-refractory disease.

      METHODS: This multicentre, open-label substudy was done at 19 sites in seven countries in ...

      Known for Ibrutinib Patients | 3 Trial | Refractory Waldenström | Treatment Disease | Median Progression
      KOL-Index: 11790

      BACKGROUND: Medical oncologists often must deliver bad news. The authors were interested in the extent of formal training in delivering bad news in hematology/oncology fellowships in the United States.

      METHODS: An e-mail survey was sent to all hematology/oncology fellowship program directors in the United States. Surveys were e-mailed to 124 program directors and responses were received either via e-mail or regular mail. Program directors were asked the adequacy, the perceived necessity, ...

      Known for Program Directors | Formal Training | United States | Graduate Fellowships | Delivering News
      KOL-Index: 11504

      Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation BTK inhibitor, with zanubrutinib, a novel highly selective BTK inhibitor, in patients with WM. Patients with MYD88L265P disease were randomly assigned 1:1 to treatment with ibrutinib or zanubrutinib. The primary end point was the proportion of patients achieving a complete ...

      Known for Waldenström Macroglobulinemia | Randomized Phase | 3 Trial | Zanubrutinib Ibrutinib | Aspen Study
      KOL-Index: 11181

      Smoking has been postulated as an environmental risk factor for acute myeloid leukemia (AML). The primary objective of this meta-analysis of observational studies was to evaluate the epidemiologic relationship between smoking and the risk of development of AML. Twenty-three studies published between January 1993 and December 2013 were included in our analysis, and accounted for 7,746 cases of AML. The outcome of interest was the relative risk (RR) with 95% confidence interval (CI) of ...

      Known for Cigarette Smoking | Acute Myeloid Leukemia | Epidemiological Studies | Risk Aml | 95 Confidence Interval
      KOL-Index: 11179

      Next-generation sequencing has revealed recurring somatic mutations in Waldenström macroglobulinemia (WM). Commonly recurring mutations include MYD88 (95% to 97%), CXCR4 (30% to 40%), ARID1A (17%), and CD79B (8% to 15%). Diagnostic discrimination of WM from overlapping B-cell malignancies is aided by MYD88 mutation status. Transcription is affected by MYD88 and CXCR4 mutations and includes overexpression of genes involved in VDJ recombination, CXCR4 pathway signaling, and BCL2 family ...

      Known for Waldenström Macroglobulinemia | Cxcr4 Mutations | Patients Wm | Mutated Myd88 | Mutation Status
      KOL-Index: 10789

      BACKGROUND.: Prognostic factors and outcomes in patients with marginal zone lymphoma (MZL) have been studied in small cohort studies, which may not reflect the population at large. METHODS.: Clinical characteristics and survival outcomes of adult patients with MZL who were diagnosed between 1995 and 2009 were evaluated using the Surveillance, Epidemiology, and End Results (SEER) database. The authors generated clinical prognostic models for subtypes of MZL and compared survival during ...

      Known for Patients Nmzl | Zone Lymphoma | Survival Outcomes | Bcell Mzl | Clinical Characteristics
      KOL-Index: 10140

      Hyponatremia, a common electrolyte abnormality in oncology practice, may be a negative prognostic factor in cancer patients based on a systematic analysis of published studies. The largest body of evidence comes from small-cell lung cancer (SCLC), for which hyponatremia was identified as an independent risk factor for poor outcome in six of 13 studies. Hyponatremia in the cancer patient is usually caused by the syndrome of inappropriate antidiuretic hormone (SIADH), which develops more ...

      Known for Hyponatremia Siadh | Cancer Patient | Fluid Restriction | Arginine Vasopressin | Ectopic Production
      KOL-Index: 10117

      MYD88 L265P is highly prevalent in Waldenstrom’s Macroglobulinemia (WM) and IgM monoclonal gammopathy of unknown significance (MGUS). We investigated whether MYD88 L265P could be identified by peripheral blood (PB) allele-specific PCR. MYD88 L265P was detected in untreated WM (114/118; 96.6%); previously treated WM (63/102; 61.8%); and IgM MGUS (5/12; 41.7%) but in none of 3 hyper-IgM or 40 healthy individuals. Median PB MYD88 L265P ΔCt was 3.77, 7.24, 10.89, 12.33 and 14.07 for ...

      Known for Myd88 L265p | Undetermined Significance | Peripheral Blood | Igm Monoclonal | Untreated Wm
      KOL-Index: 10039

      Bortezomib frequently produces severe treatment-related peripheral neuropathy (PN) in Waldenström's macroglobulinemia (WM). Carfilzomib is a neuropathy-sparing proteasome inhibitor. We examined carfilzomib, rituximab, and dexamethasone (CaRD) in symptomatic WM patients naïve to bortezomib and rituximab. Protocol therapy consisted of intravenous carfilzomib, 20 mg/m2 (cycle 1) and 36 mg/m(2) (cycles 2-6), with intravenous dexamethasone, 20 mg, on days 1, 2, 8, and 9, and rituximab, 375 ...

      Known for Carfilzomib Rituximab | Waldenströms Macroglobulinemia | 1 2 | Maintenance Therapy | Follow Studies
      KOL-Index: 9740

      BACKGROUND: Optimal frontline therapy for peripheral T-cell lymphoma (PTCL) in the modern era remains unclear.

      PATIENTS AND METHODS: We examined patient characteristics, treatment, and outcomes among 341 newly diagnosed PTCL patients from 2000 to 2011. Outcome was compared with a matched cohort of diffuse large B-cell lymphoma (DLBCL) patients, and prognostic factors were assessed using univariate and multivariate analyses.

      RESULTS: PTCL subtypes included PTCL, not otherwise specified ...

      Known for Cell Lymphoma | Frontline Therapy | Multivariate Analysis | Ptcl Patients | Sct Pfs

      Key People For Waldenström Macroglobulinemia

      Top KOLs in the world
      Steven Peter Treon
      waldenström macroglobulinemia consultancy funding patients wm
      Meletios‐Athanassios Dimopoulos
      multiple myeloma consultancy honoraria board directors
      Robert A Kyle
      multiple myeloma undetermined significance consultancy funding
      Morie Abraham A Gertz
      multiple myeloma consultancy funding stem cell
      Zachary R Hunter
      waldenström macroglobulinemia wm patients myd88 l265p
      Irene M Ghobrial
      multiple myeloma board directors advisory committees

      Jorge J Castillo:Expert Impact

      Concepts for whichJorge J Castillohas direct influence:Waldenström macroglobulinemia,  Patients wm,  Mutated myd88,  Multiple myeloma,  Latin america,  Waldenström macroglobulinaemia,  Wm patients,  Ibrutinib monotherapy.

      Jorge J Castillo:KOL impact

      Concepts related to the work of other authors for whichfor which Jorge J Castillo has influence:Cell lymphoma,  Multiple myeloma,  Waldenström macroglobulinemia,  Diffuse large,  Chronic lymphocytic leukemia,  Barr virus,  Bone marrow.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. | Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; | Hematology, Dana Far

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.